Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300482 · ClinicalTrials.gov registry record · Phase 3
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
A Phase 3 study of Dyslipidemia and Coronary Heart Disease, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,445
- Enrollment target
- 1
- Study location
NCT00300482 is a Phase 3 study of Dyslipidemia and Coronary Heart Disease that has completed, run by Abbott. The registered enrollment target is 1,445 participants, above the 327-participant average among 40 other Dyslipidemia trials with a reported enrollment target (342% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00300482, a Phase 3 study of Dyslipidemia and Coronary Heart Disease, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,445 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid levels in the blood.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ABT-335
- DRUG Rosuvastatin Calcium
Study Locations (1)
Illinois
- Global Medical Information - North Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,445 participants |
| Start Date | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300482
The ClinicalTrials.gov registry entry for NCT00300482 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,445 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 327-participant average among 40 other Dyslipidemia trials with a reported enrollment target (342% higher). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Dyslipidemia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00300482 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00300482 about?
NCT00300482 is a clinical study titled "Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood". The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid levels in the blood.
What is the current status of trial NCT00300482?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,445 participants. The study started on 2006-03.
What conditions does trial NCT00300482 study?
This clinical trial studies the following conditions: Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia.
What interventions are being tested in trial NCT00300482?
The interventions under investigation include: Placebo (DRUG), ABT-335 (DRUG), Rosuvastatin Calcium (DRUG).
Who is sponsoring clinical trial NCT00300482?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00300482 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
COMPLETED · Phase 3
-
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
COMPLETED · Phase 3
-
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
COMPLETED · Phase 3
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Cottonseed Oil Versus Matched PUFA Effects
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.